Trust Bio-sonics Completes Final Patient Enrollment for Phase III Trial of TBS-002 Ultrasound Contrast Agent
Date: 2025/ 12/ 17 Wed., Media: Global Bio & Investment
News Link：
Trust Bio-sonics has announced the successful completion of the final patient enrollment for the Phase III clinical trial of its lead drug candidate, TBS-002, in Taiwan. The trial results are expected to be unblinded in the second quarter of up-coming year, paving the way for a New Drug Application (NDA) in Taiwan and other countries.
In a simultaneous milestone, Trust Bio-sonics was invited by the Radiological Society of North America (RSNA)—the global leader in radiological imaging—to present its latest research findings in ultrasound-mediated drug delivery. The company showcased its pioneering image-guided drug delivery technology to international medical experts, highlighting its therapeutic potential for hard-to-treat cancers, including pancreatic cancer.
- Check the news link for full details -
